Drug Trial Radar · NCT04406649
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
Last checked: Nov 19, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
482
Actual
Start
Sep 14, 2020
Primary completion
Jan 16, 2023
Study completion Jan 16, 2023
Sponsor
- Lead sponsor
- Satsuma Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
Conditions
- Migraine
- Migraine With Aura
- Migraine Without Aura
Interventions
DihydroergotamineDrug
Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Attacks With Sustained Freedom From Headache Pain 2-48 Hours (Modified Intent to Treat Population)Time frame: At Month 12 of Study Medication Dosing
- Percentage of Participants With Attacks With Sustained Freedom From Most Bothersome Symptom 2-48 Hours (Modified Intent to Treat Population)Time frame: At Month 12 of Study Drug Administration
Locations
44 sites in 1 country. Site status is shown where the registry gives one.
WR-PRI
Encino, California
Collaborative Neuroscience
Long Beach, California
WR-PRI
Los Alamitos, California
Downtown LA Research
Los Angeles, California
Clinical Research Institute
Los Angeles, California
WR-PRI
Newport Beach, California
Hillcrest Medical Research
DeLand, Florida
MD Clinical
Hallandale, Florida
Multi-Specialty Research Associates
Lake City, Florida
ClinCloud
Maitland, Florida
Biotech Pharmaceuticals
Miami, Florida
Behavioral Clinical Research
Miami Lakes, Florida
CNS Health Care - Orlando
Orlando, Florida
Complete Health Research
Ormond Beach, Florida
Infinity Clinical Research
Sunrise, Florida
Santos Research Center, Corp
Tampa, Florida
Palm Beach Research Center
West Palm Beach, Florida
Clinical Research CF
Winter Haven, Florida
Advanced Clinical Research
Meridian, Idaho
Integrated Clinical Trial Services, Inc
West Des Moines, Iowa
Delricht Research
Prairieville, Louisiana
Medvadis Research at Boston PainCare Center
Waltham, Massachusetts
Healthcare Research Network
Hazelwood, Missouri
Clinvest Research
Springfield, Missouri
Montana Medical Research
Missoula, Montana
Wake Research - Clinical Research Center of Nevada
Las Vegas, Nevada
Dartmouth-Hitchcock Neurology Headache Clinic
Lebanon, New Hampshire
Hassman Research Institute
Berlin, New Jersey
Albuquerque Clinical Trials
Albuquerque, New Mexico
SPRI Clinical Research
Brooklyn, New York
Montefiore Medical Center
The Bronx, New York
PharmQuest
Greensboro, North Carolina
PMG Research of Wilmington
Wilmington, North Carolina
CTI Clinical Research Center
Cincinnati, Ohio
Rapid Medical Research
Cleveland, Ohio
Neurology Diagnosis
Dayton, Ohio
Delricht Research
Tulsa, Oklahoma
Thomas Jefferson University/Jefferson Headache Center
Philadelphia, Pennsylvania
Omega Medical Research
Warwick, Rhode Island
CNS Healthcare - Memphis
Memphis, Tennessee
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.